The Falsified Medicines Directive

At the end, the dispensing healthcare institution must verify and decommission that product against a national hub, known as the National Medicines Verification System (NMVS).
This leaves the middle of the supply chain, where there is also a requirement for wholesalers, distributors and logistics providers to implement a ‘risk-based’ approach to the verification and decommissioning of products passing through their operation. To be compliant, manufacturers, wholesalers and distributors alike will have to make changes to their supply chain operations.
Yet, despite the impending deadline the market doesn’t appear to be advanced enough in its response. When it comes to the practical application of FMD, there are many areas that still cause confusion. Organisations can no longer afford to let these areas act as barriers to implementing robust FMD solutions. Christian Taylor, Serialisation Business Consultant, Zetes, clears up some of the key pain points.
Automated workflow: Putting confusion aside, organisations should proactively be looking to implement solutions that create minimum disruption to current working processes, drive efficiencies and are simple to use every day. Whilst some of the details around the legislation will require further clarification, businesses need to ensure they have a robust solution in place to ensure compliance and remove any chance for human error.
From batch to unit level visibility: The important thing for organisations to consider at this time is that currently, no one is handling the data of individual products on the line. To be compliant and report to the national hubs, wholesalers, distributors and logistics partners are going to have to review current processes and ensure they can handle data for any single unit within their operations.
Visibility imperative: Behind this legislation, there are distinct efficiency and quality advantages to be found. Wholesalers, distributors and logistics partners should use this opportunity to improve capability within the warehouse and business operations.
Sign up for your free email newsletter
Building a comprehensive and agile visibility layer on existing processes and cross-functional systems. This will not only ensure compliance by 9 February 2019, but these infrastructures can be built upon further, putting organisations in a better position to react to any further regulation changes with ease.
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Treat Acidity: Use medicines with this Pepto Bismol Active Ingredient
-
The battle for Medicine King! With the onslaught of K drug and the setback of Xiomele, the biggest variable in the world's TOP10 drug rankings in 2022 is who?
-
Facing Omicron, Where is the Next 'Special Medicine'?
-
What Are the Medicine that Requires Refrigeration? All You Need Know
-
China to focus on building quality and efficient TCM service system in next five years
-
Overwhelming influx of alliance procurement: orthopaedics and IOLs
-
Analysis of domestic veterinary drug raw materials market in the 42nd week of 2021 Part 2
-
How far is Chinese patent medicine from the ground?
-
Chinese medicine enters the era of plant extraction
-
Analysis of Import and Export of Chinese Medicines in 2019
Recommend Reading
-
Hormuz Closure Raises Cold-Chain Risk
-
Middle East Conflict Hits China Seafood Trade
-
US Tariff Refunds Could Reshape Seafood Trade
-
Hormuz Closure Raises Cold-Chain Risk
-
Hormuz Disruptions Affect Nearly 20% of Global Ethylene Capacity as Polyethylene Supply Tightens
-
Business Society October 15, 2026 Propylene Oxide Trend Analysis: Strong Consolidation (Bullish)
-
Business Society October 16, 2026 DOP Trend Analysis: Moderately Bearish
-
Business Society October 15, 2026 Maleic Anhydride Trend Analysis: Volatility
-
Business Society, October 15, 2026: Cyclohexane Market Outlook—Bullish
-
Business Society October 16, 2026 Phenol Trend Analysis: Weakly Tending